Patient registries are more than just databases or collections of data. Registries are powerful tools that can transform real-world clinical, social, and patient-reported data into actionable insights. Without high-quality and secure registries, we risk poorer patient outcomes, slower research progress, and a less equitable and effective health system.
As a member of the Future of Registries Taskforce (FoRT), Alpha-1 Foundation Ireland is pleased to announce the launch of a new report titled “Sustaining Patient Registries in Ireland”. The new report outlines a roadmap for establishing a sustainable, cost-efficient registry model to improve patient care and support health care research, policy and practice. Examples of several patient registries are included in Appendix 5, including our own Alpha-1 Registry.
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
WhatisAlpha-1AntitrypsinDeficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
HowDoIGetTested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie
New Report on Patient Registries Launched
Patient registries are more than just databases or collections of data. Registries are powerful tools that can transform real-world clinical, social, and patient-reported data into actionable insights. Without high-quality and secure registries, we risk poorer patient outcomes, slower research progress, and a less equitable and effective health system.
As a member of the Future of Registries Taskforce (FoRT), Alpha-1 Foundation Ireland is pleased to announce the launch of a new report titled “Sustaining Patient Registries in Ireland”. The new report outlines a roadmap for establishing a sustainable, cost-efficient registry model to improve patient care and support health care research, policy and practice. Examples of several patient registries are included in Appendix 5, including our own Alpha-1 Registry.
To read the report click here.
For more information on the National Alpha-1 Registry, visit https://www.alpha1.ie/irish-alpha-1-registry/.
Info Centre
What is Alpha-1 Antitrypsin?
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
What is Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
How Do I Get Tested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie